SRC Stock Recent News

Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Stakeholder Gold Corp. (TSXV: SRC) (OTC Pink: SKHRF)  ("Stakeholder" or the "Company") is pleased to announce that the Company has submitted a Class 1 Notification for 2025 exploration on the Ballarat Gold-Copper Project; including maiden drilling on the Skye Gold Zone and the Loki Copper Zone. Ballarat Exploration Program 2025 The Company is planning to drill 2,500 meters over 8 - 10 drill holes targeting two previously identified and documented zones of mineralization, the Skye Gold Zone and the Loki Copper Zone.

Toronto, Ontario--(Newsfile Corp. - February 13, 2025) - Stakeholder Gold Corp. (TSXV: SRC) (OTC Pink: SKHRF) ("Stakeholder" or the "Company") is pleased to announce first sales from the Company's third quarry in Minas Gerais, Brazil. The quarry produces white quartzite blocks for cutting and polishing into slabs.

Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.

Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Stakeholder Gold Corp. (TSXV: SRC) ("Stakeholder" or the "Company") is pleased to announce results and interpretation for the VLF-EM (Very Low Frequency - Electro-Magnetic) geophysical survey undertaken on the Company's 100% owned Ballarat Gold-Copper Project ("Ballarat") which covers 18,741 Ha in the Heart of the White Gold District of the Yukon Territory, Canada. The VLF-EM survey was a portion of the 2024 summer exploration program on Ballarat.

Since our last analysis, Realty Income has delivered a 17.2% return and completed its merger with Spirit Realty Capital. As the interest rate environment transitions to a rate-cutting cycle, the company's growth prospects are on the rise. DCF analysis shows conservative growth estimates, factoring in historical growth rates and recent mergers, with AFFO providing a clear view of sustainable earnings.

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.

Spirit Realty Capital shareholders have approved the merger deal. The deal is expected to be positive for Realty Income and will result in sizable AFFO per share accretion. The merger will diversify Realty Income's portfolio and lower rent concentration for top industries and clients.

REITs faced challenges in 2023 but rebounded late in the year. The bull thesis for REITs includes attractive valuations, fading interest rate headwinds, and a moderately strong macro environment. We disagree on all three fronts and hence are downgrading both Realty Income Corporation and Spirit Realty Capital, Inc. stock.

Spirit Realty (SRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Realty Income has agreed to buy peer Spirit Realty in an all-stock deal. It will take on Spirit's $4.1 billion in debt.